EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Early Peripheral Blood WT1 Expression Predicts Relapse After Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia

Viktor Blaslov, Margareta Radic Antolic, Ivana Horvat, Tamara Vasilj, Zeljko Prka, Antonija Miljak, Davor Galusic, Lucana Vicelic Cutura, Marija Petric, Alen Ostojic iD, Pavle Roncevic, Iva Ivanko und 9 weitere

International Journal of Molecular Sciences · 14.05.2026 · 27 (10) · 4367

DOI: 10.3390/ijms27104367 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 14.05.2026. Verfasst von Viktor Blaslov und 20 weiteren Autor:innen. Beteiligte Einrichtung: University Hospital of Split, Spinciceva 1, 21000 Split, Croatia. Hauptthemen laut MEDLINE: WT1 Proteins, Hematopoietic Stem Cell Transplantation, Leukemia, Myeloid, Acute, Biomarkers, Tumor. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: KROHEM—The Foundation of the Croatian Cooperative Group for Hematological Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Relapse remains the leading cause of treatment failure after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML). Early identification of patients at increased post-transplant relapse risk is essential to enable intensified surveillance and pre-emptive therapeutic strategies. Wilms’ tumor 1 (WT1) is overexpressed in most AML cases and represents a broadly applicable molecular marker; however, its utility as a peripheral blood (PB) measurable residual disease (MRD) marker after allo-HSCT remains incompletely defined. In this prospective multicenter cohort study, 43 adults with AML in complete remission underwent allo-HSCT between 2021 and 2023. WT1 expression in PB was quantified using standardized real-time quantitative PCR before transplantation (WT1_pre) and at day +30 (WT1_30). Receiver operating characteristic analysis identified an optimal threshold for relapse prediction. A WT1 cutoff of ≥3 copies/104 ABL discriminated relapse risk. WT1_30 demonstrated strong prognostic performance (AUC 0.79; p = 0.005), whereas WT1_pre showed more modest predictive value (AUC 0.69; p = 0.037). Patients with WT1_30 ≥ 3 had inferior 12-month progression-free survival compared with those with WT1_30 < 3 (52.9% vs. 90.9%, p = 0.0059) and a higher 12-month cumulative incidence of relapse (31% vs. 9%, p = 0.054). WT1_pre ≥ 3 was also associated with inferior progression-free and overall survival (both p = 0.0008). Relapsed patients had significantly higher WT1_30 levels than non-relapsed patients (median 5.0 vs. 2.0 copies/104 ABL; p = 0.018). Peripheral blood WT1 expression, particularly at day +30, is associated with an increased relapse risk after allo-HSCT in AML and may support early post-transplant risk stratification. The identified cutoff should be considered exploratory and requires validation in larger independent cohorts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

WT1 ProteinsHematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteBiomarkers, TumorHumansTransplantation, HomologousFemaleAdultMaleRecurrenceMiddle AgedNeoplasm, ResidualPrognosisProspective StudiesYoung AdultNeoplasm Recurrence, Local

Stichwörter der Autor:innen

WT1acute myeloid leukemiaallogeneic hematopoietic stem cell transplantationmeasurable residual diseaseperipheral bloodprognostic biomarkerrelapse

Substanzen

WT1 ProteinsWT1 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • University Hospital of Split, Spinciceva 1, 21000 Split, Croatia.
  • University Hospital Centre Zagreb, 10000 Zagreb, Croatia.
  • Clinical Hospital Dubrava, 10000 Zagreb, Croatia.
  • School of Medicine, University of Split, 21000 Split, Croatia.
  • University Hospital Centre Sisters of Mercy Zagreb, 10000 Zagreb, Croatia.
  • General Hospital Sibenik, 22000 Sibenik, Croatia.

ORCID-Profile: Alen Ostojic, Ante Vulic, Mirta Mikulic, Radovan Vrhovac

Förderung

  • KROHEM—The Foundation of the Croatian Cooperative Group for Hematological Diseases

Zitieren

APA

Blaslov, V., Radic Antolic, M., Horvat, I., Vasilj, T., Prka, Z., Miljak, A., Galusic, D., Vicelic Cutura, L., Petric, M., Ostojic, A., Roncevic, P., Ivanko, I., Krecak, I., Rincic, G., Desnica, L., Serventi-Seiwerth, R., Vulic, A., Mikulic, M., Durakovic, N., …, & Peric, Z. (2026). Early Peripheral Blood WT1 Expression Predicts Relapse After Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia. International Journal of Molecular Sciences, 27(10), 4367. https://doi.org/10.3390/ijms27104367

Vancouver

Blaslov V, Radic Antolic M, Horvat I, Vasilj T, Prka Z, Miljak A, et al. Early Peripheral Blood WT1 Expression Predicts Relapse After Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia. International Journal of Molecular Sciences. 2026;27(10):4367. doi:10.3390/ijms27104367

BibTeX
@article{Blaslov2026,
  author = {Blaslov, Viktor and Radic Antolic, Margareta and Horvat, Ivana and Vasilj, Tamara and Prka, Zeljko and Miljak, Antonija and Galusic, Davor and Vicelic Cutura, Lucana and Petric, Marija and Ostojic, Alen and Roncevic, Pavle and Ivanko, Iva and Krecak, Ivan and Rincic, Goran and Desnica, Lana and Serventi-Seiwerth, Ranka and Vulic, Ante and Mikulic, Mirta and Durakovic, Nadira and Vrhovac, Radovan and Peric, Zinaida},
  title = {Early Peripheral Blood WT1 Expression Predicts Relapse After Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {10},
  pages = {4367},
  doi = {10.3390/ijms27104367}
}
Kostenlos starten →